Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...

On February 6, 2025, Sanofi has entered into a mandate with an investment service provider for the second tranche of this program. Under the terms of this mandate, Sanofi will repurchase its own ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...